(CLVT) CLARIVATE - Overview
Sector: Technology | Industry: Information Technology Services | Exchange: NYSE (USA) | Market Cap: 1.566m USD | Total Return: -41.1% in 12m
Avg Turnover: 12.3M
EPS Trend: -86.6%
Qual. Beats: 0
Rev. Trend: -94.6%
Qual. Beats: 0
Warnings
Interest Coverage Ratio 0.5 is critical
Altman Z'' -1.51 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
Clarivate Plc is a global information services provider headquartered in London, operating through three primary segments: Academia & Government, Intellectual Property (IP), and Life Sciences & Healthcare. The company specializes in curating proprietary data and providing AI-native analytics tools, such as Web of Science and Derwent Innovation, to support research, patent management, and regulatory compliance.
The business model relies heavily on a subscription-based revenue stream, which typically provides high visibility into recurring cash flows. As a player in the Research & Consulting Services sub-industry, Clarivate functions as a critical infrastructure provider for academic institutions and pharmaceutical companies that require validated datasets for long-term R&D cycles.
For a more granular look at how these recurring revenue streams impact long-term valuation, consider reviewing the detailed metrics available on ValueRay.
The company’s IP segment offers specialized services including patent maintenance, trademark evaluation, and risk assessment through its CompuMark and IPfolio platforms. This positioning allows Clarivate to capture value across the entire innovation lifecycle, from initial scientific discovery to the protection of commercial intellectual property.
- Subscription renewal rates across academic and intellectual property segments drive recurring revenue
- AI integration in patent and research platforms improves operational efficiency and margins
- High leverage and interest expense levels impact net income and capital allocation
- Global research and development spending cycles influence demand for data analytics tools
- Strategic divestitures and portfolio optimization efforts determine long-term earnings growth potential
| Net Income: -137.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 2.37 > 1.0 |
| NWC/Revenue: -9.85% < 20% (prev -7.37%; Δ -2.48% < -1%) |
| CFO/TA 0.05 > 3% & CFO 592.0m > Net Income -137.4m |
| Net Debt (4.15b) to EBITDA (878.3m): 4.73 < 3 |
| Current Ratio: 0.84 > 1.5 & < 3 |
| Outstanding Shares: last quarter (640.7m) vs 12m ago -7.12% < -2% |
| Gross Margin: 66.54% > 18% (prev 0.66%; Δ 6.59k% > 0.5%) |
| Asset Turnover: 21.83% > 50% (prev 22.01%; Δ -0.18% > 0%) |
| Interest Coverage Ratio: 0.47 > 6 (EBITDA TTM 878.3m / Interest Expense TTM 260.1m) |
| A: -0.02 (Total Current Assets 1.30b - Total Current Liabilities 1.54b) / Total Assets 10.9b |
| B: -0.69 (Retained Earnings -7.55b / Total Assets 10.9b) |
| C: 0.01 (EBIT TTM 122.5m / Avg Total Assets 11.2b) |
| D: 0.78 (Book Value of Equity 4.79b / Total Liabilities 6.14b) |
| Altman-Z'' = -1.51 = D |
| DSRI: 1.10 (Receivables 882.9m/830.5m, Revenue 2.45b/2.53b) |
| GMI: 0.99 (GM 66.54% / 66.06%) |
| AQI: 1.00 (AQ_t 0.87 / AQ_t-1 0.87) |
| SGI: 0.97 (Revenue 2.45b / 2.53b) |
| TATA: -0.07 (NI -137.4m - CFO 592.0m) / TA 10.9b) |
| Beneish M = -3.04 (Cap -4..+1) = AA |
As of May 25, 2026, the stock is trading at USD 2.45 with a total of 2,700,897 shares traded.
Over the past week, the price has changed by +1.24%,
over one month by +0.00%,
over three months by +4.26% and
over the past year by -41.11%.
CLARIVATE has received a consensus analysts rating of 3.70. Therefore, it is recommended to hold CLVT.
- StrongBuy: 3
- Buy: 2
- Hold: 4
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 3.6 | 48.6% |
P/E Forward = 3.6298
P/S = 0.64
P/B = 0.327
P/EG = 0.178
Revenue TTM = 2.45b USD
EBIT TTM = 122.5m USD
EBITDA TTM = 878.3m USD
Long Term Debt = 4.28b USD (from longTermDebt, last quarter)
Short Term Debt = 19.1m USD (from shortTermDebt, last quarter)
Debt = 4.39b USD (from shortLongTermDebtTotal, last quarter) + Leases 51.3m
Net Debt = 4.15b USD (calculated: Debt 4.39b - CCE 232.3m)
Enterprise Value = 5.72b USD (1.57b + Debt 4.39b - CCE 232.3m)
Interest Coverage Ratio = 0.47 (Ebit TTM 122.5m / Interest Expense TTM 260.1m)
EV/FCF = 9.58x (Enterprise Value 5.72b / FCF TTM 597.1m)
FCF Yield = 10.44% (FCF TTM 597.1m / Enterprise Value 5.72b)
FCF Margin = 24.40% (FCF TTM 597.1m / Revenue TTM 2.45b)
Net Margin = -5.62% (Net Income TTM -137.4m / Revenue TTM 2.45b)
Gross Margin = 66.54% ((Revenue TTM 2.45b - Cost of Revenue TTM 818.7m) / Revenue TTM)
Gross Margin QoQ = 67.19% (prev 66.81%)
Tobins Q-Ratio = 0.52 (Enterprise Value 5.72b / Total Assets 10.9b)
Interest Expense / Debt = 5.93% (Interest Expense 260.1m / Debt 4.39b)
Taxrate = 21.0% (US default 21%)
NOPAT = 96.8m (EBIT 122.5m * (1 - 21.00%))
Current Ratio = 0.84 (Total Current Assets 1.30b / Total Current Liabilities 1.54b)
Debt / Equity = 0.92 (Debt 4.39b / totalStockholderEquity, last quarter 4.79b)
Debt / EBITDA = 4.73 (Net Debt 4.15b / EBITDA 878.3m)
Debt / FCF = 6.96 (Net Debt 4.15b / FCF TTM 597.1m)
Total Stockholder Equity = 4.88b (last 4 quarters mean from totalStockholderEquity)
RoA = -1.23% (Net Income -137.4m / Total Assets 10.9b)
RoE = -1.10% (Net Income TTM -137.4m / Total Stockholder Equity 12.4b)
RoCE = 0.73% (EBIT 122.5m / Capital Employed (Equity 12.4b + L.T.Debt 4.28b))
RoIC = 1.03% (NOPAT 96.8m / Invested Capital 9.37b)
WACC = 6.47% (E(1.57b)/V(5.95b) * Re(11.48%) + D(4.39b)/V(5.95b) * Rd(5.93%) * (1-Tc(0.21)))
Discount Rate = 11.48% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -24.44 | Cagr: -2.08%
[DCF] Terminal Value 77.97% ; FCFF base≈500.7m ; Y1≈573.9m ; Y5≈844.7m
[DCF] Fair Price = 13.39 (EV 12.7b - Net Debt 4.15b = Equity 8.56b / Shares 639.2m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -86.65 | EPS CAGR: -25.13% | SUE: 0.34 | # QB: 0
Revenue Correlation: -94.58 | Revenue CAGR: -2.65% | SUE: 0.73 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.18 | Chg30d=-3.99% | Revisions=-45% | Analysts=8
EPS next Quarter (2026-09-30): EPS=0.18 | Chg30d=-3.23% | Revisions=-40% | Analysts=8
EPS current Year (2026-12-31): EPS=0.73 | Chg30d=+2.09% | Revisions=+38% | GrowthEPS=+6.0% | GrowthRev=-3.7%
EPS next Year (2027-12-31): EPS=0.78 | Chg30d=-0.06% | Revisions=-8% | GrowthEPS=+6.9% | GrowthRev=+2.2%
[Analyst] Revisions Ratio: -45%